If you have spent any time on YouTube, podcasts, or supplement Twitter, you have heard three voices dominate the NMN conversation: David Sinclair, Andrew Huberman, and Peter Attia. Their combined audience runs into tens of millions, and their NMN takes have moved Malaysian buying patterns more than any pharmacy advert. But influence is not evidence. This fact-check separates each figure’s strongest claims from what the published 2018-2026 literature actually supports.
David Sinclair: the originator
David Sinclair is a Harvard Medical School geneticist whose 2013 Cell paper on NMN and SIRT1 in mice catalysed global interest in the molecule. His credentials are real and his lab work peer-reviewed.
Where claims drift is in his media appearances. Sinclair has stated personal use of approximately 1 gram of NMN daily for years and described feeling like he has reversed his biological age. The personal experience is his own. The extrapolation to public recommendation is where the gap appears.
His own published human trial output on NMN remains modest. Mouse data such as Mills 2016 demonstrated NAD+ rises and metabolic improvements, but mouse-to-human translation is famously unreliable. Yoshino 2021 in postmenopausal women showed insulin sensitivity gains, not the lifespan extension Sinclair sometimes implies.
Verdict: Sinclair’s lab papers are evidence-grade. His podcast statements are personal protocol, not validated public guidance.
Andrew Huberman: the populariser
Andrew Huberman is a Stanford neurobiologist whose podcast has popularised NMN among general audiences. His citations are usually accurate. He references the Imai-led NAD+ decline literature, the Liao 2021 amateur runner trial, and the Igarashi 2022 older men trial.
Where Huberman’s reach can mislead is in clip culture. A 90-minute episode with appropriate caveats is condensed into 30-second TikTok snippets that strip the hedges. The viewer hears “NMN improves muscle function” without the trial-design context (12 weeks, healthy older men, modest effect size).
Huberman has also occasionally conflated NMN and nicotinamide riboside (NR) effects when speaking quickly. They share end points (NAD+) but differ in entry kinetics and bioavailability. See our NMN vs NR explainer for the distinction.
Verdict: Generally accurate when listened to in full; misleading when consumed as clips.
Peter Attia: the recalibrator
Peter Attia, longevity-focused physician, has been the most evolutionary in his stance. In early podcasts circa 2020-2022 he was cautiously supportive of NMN supplementation. By 2024-2025 his tone shifted toward dose-skepticism, citing the lack of long-term human data and the cost-benefit unfavourability for unproven mechanisms.
His shift is not a contradiction. It reflects what good evidence-based medicine looks like: updating priors as data fails to arrive. The expected wave of large-cohort NMN trials anticipated post-2022 has not materialised at the scale early enthusiasts predicted.
Attia’s current position can be summarised as: NMN is probably not harmful at studied doses, but the case for buying it at premium prices versus simpler interventions (exercise, sleep, niacinamide as a cheap alternative) is weaker than the influencer consensus suggests.
Verdict: Currently the most evidence-anchored of the three voices.
How to read longevity influencer claims
Three filters help:
- Is the cited paper mouse or human? Mouse data is hypothesis-generating, not prescriptive.
- Sample size and duration? A 12-week trial with 30 participants cannot prove lifespan claims.
- Conflict of interest disclosure? Some commentators have equity in NMN brands. Always check the show notes.
For a clean reading list of the strongest NMN human trials, see our science guide and dosage guide.
Where the actual evidence stands in 2026
Cumulative human evidence on NMN includes:
- Yoshino 2021: 25 postmenopausal women, 250 mg/day, 10 weeks, improved muscle insulin sensitivity
- Igarashi 2022: 42 older men, up to 250 mg/day, 12 weeks, alterations in muscle function
- Liao 2021: 48 amateur runners, up to 1200 mg/day, 6 weeks, aerobic capacity improvement
- Pooled smaller trials: dose-dependent NAD+ rise, no major safety signal at studied doses
What is missing: large-cohort multi-year trials, hard endpoint data (mortality, cardiovascular events), and validation of the lifespan extrapolation from mouse models.
Bottom line for Malaysian readers
David Sinclair, Andrew Huberman, and Peter Attia have shaped global NMN buying. Sinclair leans optimistic beyond published evidence. Huberman is generally careful but vulnerable to clip culture. Attia has recalibrated toward skepticism as data has stalled. None of them substitute for reading the actual papers. If you choose to supplement, do so based on the trial-design questions above, not on the loudness of any single voice. For a structured purchase decision tree see our buying guide.